The global nonvenereal syphilis treatment market is estimated to grow at a notable CAGR over the forecast period, i.e., 2022 – 2030. Non-venereal syphilis, also known as bejel, is an endemic caused by the same bacteria that causes syphilis. The growth of the market can be attributed to the increasing prevalence and awareness regarding non-venereal syphilis. This syphilis is not transmitted sexually, however, it can be transmitted orally, from mouth to mouth, or by sharing utensils. The bacteria treponema pallidum infects the skin and tissues, especially the mucosa layer inside the nose and mouth, resulting in callus, patch, or abscess on the face. The severe symptoms include lesions on the face, limbs, head, or testicles, and inflammation, along with infection that may spread to the bones and internal tissues. The growing incidences of bejel, is estimated to boost the market growth. According to the statistics of Center of Disease Control and Prevention, 129,813 cases of all stages of syphilis, were reported in 2019, globally. As per the data by World Health Organization, over 80,000 cases of bejel are reported each year. Moreover, the increasing demand for treatment, backed by the rapid pace of infection transmission, is estimated to boost the market growth.
The global nonvenereal syphilis treatment market is segmented by treatment into antibiotics, topical treatment, and others, out of which, the antibiotics segment is anticipated to hold the notable share in the market over the forecast period on account of easy availability of broad-spectrum antibiotics, such as, penicillin, and fast overall action of the drug. Moreover, antibiotics can kill the infection from its root cause and provide lost-lasting relief. This is estimated to boost the segment growth. CLICK TO DOWNLOAD SAMPLE REPORT
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
On the basis of geographical analysis, the global nonvenereal syphilis treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in Middle East and Africa region is estimated to witness noteworthy growth over the forecast period on the back of high prevalence of nonvenereal syphilis in regions of west Africa, Mediterranean, and Sahara. Lack of sanitization, hot and humid climate, and lack of proper healthcare services in the region, are estimated to boost the market growth.
The market in the Asia Pacific region is anticipated to gain the largest market share throughout the forecast period owing to the growing cases of bejel in underdeveloped areas of the APAC region, including, Nepal, Myanmar, Cambodia, Bangladesh, and parts of India.
The global nonvenereal syphilis treatment market is further classified on the basis of region as follows:
Our in-depth analysis of the global nonvenereal syphilis treatment market includes the following segments:
FREQUENTLY ASKED QUESTIONS
The growing cases of the disease in Middle East and Africa region are estimated to boost the market growth.
The market is anticipated to attain a notable CAGR over the forecast period, i.e., 2022 – 2030.
Lack of efficient healthcare system is estimated to hamper the market growth.
The market in the Middle East and Africa region will provide more business opportunities over the forecast period owing to the growing prevalence of nonvenereal syphilis in the region.
The major players in the market are Mylan N.V., Novartis International AG, Sanofi S.A., GlaxoSmithKline plc, Merck & Co., Inc., Otsuka Pharmaceutical Co., Ltd., Abbott Laboratories, Cipla Limited, and others.
The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by diagnosis, treatment, and by region.
The antibiotics segment is anticipated to hold largest market size in the forecast period and display significant growth opportunities.
Select License Type
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization